ABVC Biopharma, Inc. — Form 10-Q Summary
Period covered: The filing is for the quarter ended December 31, 2015, although the request identifies it as 2016 Q1. The unaudited financial statements principally reflect the former Metu Brands, Inc. shell and its limited apparel-related operations; the BriVision business combination closed after quarter-end, on February 8, 2016. Amounts below are in U.S. dollars unless noted.
Business context and reporting period
Following the February 2016 share exchange, the company became a holding company for BriVision, a biotechnology company focused on developing drugs and medical devices, with a stated strategy of advancing candidates through proof of concept and licensing them to pharmaceutical companies. The exchange was accounted for as a reverse merger and recapitalization, with BriVision as the accounting acquirer. The quarter’s reported results therefore should not be read as BriVision’s operating results.
Financial results and position
| Metric | Three months ended Dec. 31, 2015 | Comparable 2014 period |
|---|---|---|
| Revenue | $0 | $0 |
| Gross profit | $0 | $0 |
| Operating expenses | $3,323 | $1,030 |
| Net income (loss) | $9,827 | ($1,030) |
| Operating cash flow | ($3,323) | $0 |
| Investing and financing cash flows | $0 | $0 |
2015-quarter net income resulted from $13,150 of debt-cancellation income, rather than revenue-generating operations. The filing reports no interest expense or income taxes for either quarter. Gross margin is not meaningful because revenue and cost of sales were both zero.
At December 31, 2015, cash was $37, inventory $274, current assets $311, net intangible assets $64,594, and total assets $64,905. The balance sheet reported no liabilities, compared with $39,150 of liabilities at September 30, 2015. Working capital was $311. The $7,000 note payable and $9,000 related-party note were cancelled in November and December 2015, respectively; accrued expenses also declined. The company reported no investing or financing cash flows and used $3,323 of cash in operations.
Common shares outstanding were 65,431,144 at December 31, 2015; the filing separately reports 66,422,502 as of February 18, 2016. The share-exchange terms included issuing 52,936,583 shares to BriVision shareholders and retiring 51,945,225 shares held by Euro-Asia; the filing says the BriVision shareholders held approximately 79.70% after closing.
Material changes, outlook, and risks
- Business and control change: The February 8, 2016 exchange brought BriVision under the company and replaced the former business plan. The filing describes this as a subsequent event, not part of the quarter’s historical results.
- Licensing arrangement: On December 29, 2015, BriVision entered a collaborative agreement with BioLite for U.S. and Canadian licensing rights to five drug candidates. The stated total consideration is $100 million in cash or equivalent BriVision stock, with staged payments tied to development milestones. The filing identifies BioLite’s director as the company’s CEO. It does not clearly establish what, if any, amounts had been paid or were recognized in the quarter.
- Revenue outlook: Management said most licensed products remain under development or in trials and that no near-term revenue is expected. The filing states approximately $0 of R&D spending during the “first three months of 2016”; this timing does not clearly align with the reported quarter.
- Going concern and funding: The financial-statement notes say limited operations and a working-capital deficit raise substantial doubt about the company’s ability to continue as a going concern. Management said additional capital is needed and financing is not assured; the MD&A also says funds may be insufficient to operate for the next 12 months. Equity financing could dilute shareholders.
- Controls: Management concluded disclosure controls were ineffective, citing limited financial staff and lack of segregation of duties. The company described remediation plans, including documenting and testing controls and adding financial staff, but did not assure that these steps would be sufficient.
- Other risks: The filing cites competition, pricing and margin pressure, securities-market volatility, penny-stock regulation, and risks to the development and financing plans. It reports no material off-balance-sheet arrangements and no lease commitments.
Most important facts for investors to verify
- Confirm the post-exchange capitalization, ownership percentages, share cancellations, and any subsequent share issuances.
- Review the BioLite agreement’s payment obligations, milestone conditions, related-party governance, and any payments or amendments.
- Assess available cash, actual funding needs, financing arrangements, and the going-concern disclosure.
- Check whether ineffective disclosure controls were remediated and whether any additional weaknesses were identified.
- Reconcile the filing’s period and comparative-date inconsistencies, including the “first three months of 2016” R&D statement and working-capital comparison.